<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00861029</url>
  </required_header>
  <id_info>
    <org_study_id>111485</org_study_id>
    <nct_id>NCT00861029</nct_id>
  </id_info>
  <brief_title>VEG111485: A QTc Study of Pazopanib</brief_title>
  <official_title>A Randomized, Blinded Placebo-Controlled Study to Evaluate the Effect of Repeat Oral Doses of Pazopanib (GW786034) on the Electrocardiogram (ECG) With Focus on Cardiac Repolarization (QTc Duration) in Subjects With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, randomized, double-blind, placebo-controlled, study to estimate the&#xD;
      effects of daily oral dosing of 800 mg pazopanib on electrocardiographic parameters (QTc&#xD;
      interval duration) as compared with placebo in subjects with solid tumors. Moxifloxacin, will&#xD;
      serve as a positive control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I, randomized, double-blind, placebo-controlled, parallel group study&#xD;
      designed to estimate the effects of repeated, once daily oral dosing of pazopanib on&#xD;
      electrocardiographic parameters with a particular focus on its effect on cardiac&#xD;
      repolarization (QTc interval duration) as compared with placebo in subjects with solid&#xD;
      tumors. Moxifloxacin, a drug known to cause mild QTc interval prolongation, is included as a&#xD;
      positive control to validate the ability of the study to detect a small prolongation in the&#xD;
      QTc interval. Digital 12-lead electrocardiograms (ECGs) will be extracted from continuous ECG&#xD;
      recordings obtained via a Holter monitor. The effects of pazopanib and moxifloxacin on&#xD;
      cardiac repolarization will be compared with placebo.&#xD;
&#xD;
      This study will also assess the pharmacokinetic-pharmacodynamic relationship between plasma&#xD;
      concentrations of pazopanib and its metabolites and their effects, if any, on cardiac&#xD;
      repolarization, specifically on the QT interval.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 19, 2009</start_date>
  <completion_date type="Actual">February 15, 2010</completion_date>
  <primary_completion_date type="Actual">February 15, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in QTcF interval at each time point on Study Day 9 (average of at least 3 Holter ECG replicates per time point) as compared with time-matched placebo.</measure>
    <time_frame>11 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ECG parameters: RR interval, QT, QTcB, heart rate, PR, QRS intervals and morphology.</measure>
    <time_frame>11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pazopanib and metabolites (GSK1268992, GSK1268997 and GSK1071306) concentrations and PK parameters AUC(0-t), AUC(0-24), C24 Cmax and tmax as data permit.</measure>
    <time_frame>11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in QTcF interval at each time point on Study Day 1 (average of at least 3 Holter ECG replicates per time point) as compared with time-matched placebo.</measure>
    <time_frame>11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma moxifloxacin concentrations and PK parameters AUC(0-t), AUC(0-∞), Cmax and tmax as data permit.</measure>
    <time_frame>11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety parameters: AEs, vital signs, ECGs and clinical laboratory assessments.</measure>
    <time_frame>11 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Carcinoma, Renal Cell</condition>
  <arm_group>
    <arm_group_label>Pazopanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive pazopanib during study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo as a comparator to pazopanib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib</intervention_name>
    <description>Subjects treated with pazopanib</description>
    <arm_group_label>Pazopanib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo for pazopanib</intervention_name>
    <description>Control for comparison with pazopanib</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Comparator for pazopanib</description>
    <arm_group_label>Pazopanib</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo for moxifloxacin</intervention_name>
    <description>Placebo for moxifloxacin</description>
    <arm_group_label>Pazopanib</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, age 18 years or older, at the time of signing of the informed consent.&#xD;
&#xD;
          -  Has histologically or cytologically confirmed advanced solid tumor malignancy.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.&#xD;
&#xD;
          -  Able to swallow and retain oral medication.&#xD;
&#xD;
          -  Adequate organ systems function.&#xD;
&#xD;
          -  Serum potassium level &gt;4 mEq/L, magnesium level &gt;1.7 mg/dL and total serum calcium&#xD;
             level within normal limits (if albumin is &lt;4.5 g/dL, albumin-corrected total serum&#xD;
             calcium level should be within normal limits [see Appendix 7]). NOTE: Supplementation&#xD;
             is permitted in order to meet this criterion. Subject should be retested following&#xD;
             supplementation.&#xD;
&#xD;
          -  Subject is a woman of non-childbearing potential or willing to use acceptable&#xD;
             contraception.&#xD;
&#xD;
          -  Subject is a man with a female partner of childbearing potential agrees to use&#xD;
             contraception.&#xD;
&#xD;
          -  Subject, if sexually active, agrees to continue the recommended contraception method&#xD;
             for the duration of treatment and for 28 days following discontinuation of treatment.&#xD;
&#xD;
          -  Capable of giving written informed consent.&#xD;
&#xD;
          -  The subject is able to understand and comply with protocol requirements, instructions&#xD;
             and protocol-stated restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any of the following ECG findings, QTcF interval &gt;470 msec, PR interval &gt;240 msec or&#xD;
             ≤110msec, Bradycardia defined as sinus rate &lt;50 beats per minute&#xD;
&#xD;
          -  Cardiac conduction abnormalities denoted by any of the following: Evidence of&#xD;
             second-degree (type II) or third-degree atrioventricular block, Evidence of&#xD;
             ventricular pre-excitation, Electrocardiographic evidence of complete left bundle&#xD;
             branch block (LBBB), Intraventricular conduction delay with QRS duration &gt;120 msec,&#xD;
             Atrial fibrillation, Presence of cardiac pacemaker.&#xD;
&#xD;
          -  History of any one of the following cardiovascular conditions within the past 6&#xD;
             months: Class III or IV congestive heart failure as defined by the New York Heart&#xD;
             Association (NYHA), cardiac angioplasty or stenting, myocardial infarction, unstable&#xD;
             angina, symptomatic peripheral vascular disease or other clinically significant&#xD;
             cardiac disease.&#xD;
&#xD;
          -  For subjects with a history of myocardial infarction (&gt;6 months ago), congestive heart&#xD;
             failure (&gt;6 months ago) or prior anthracycline exposure, left ventricular ejection&#xD;
             fraction (LVEF) must be assessed within 28 days prior to the first dose of study drug&#xD;
             by one of the following methods: multiple gated acquisition (MUGA) scan or&#xD;
             echocardiogram (ECHO). Subjects with a measurement of LVEF &lt;50% are excluded from&#xD;
             participation in the study.&#xD;
&#xD;
          -  Personal or family history of long-QT syndrome.&#xD;
&#xD;
          -  History or clinical evidence of CNS metastases or leptomeningeal carcinomatosis,&#xD;
             except for individuals who have previously treated CNS metastases, are asymptomatic,&#xD;
             and have had no requirement for steroids or anti-seizure medication for 2 months prior&#xD;
             to beginning study treatment.&#xD;
&#xD;
          -  Clinically significant gastrointestinal (GI) abnormalities that may affect the&#xD;
             absorption of study drug including, but not limited to: malabsorption syndrome, major&#xD;
             resection of the stomach or small bowel.&#xD;
&#xD;
          -  Clinically significant GI abnormalities that may increase the risk for GI bleeding&#xD;
             including, but not limited to: active peptic ulcer disease, known intra-luminal&#xD;
             metastatic lesion(s) with suspected bleeding, inflammatory bowel disease, ulcerative&#xD;
             colitis or other GI conditions with increased risk of perforation, history of&#xD;
             abdominal fistula, GI perforation or intra-abdominal abscess within 28 days prior to&#xD;
             beginning study treatment.&#xD;
&#xD;
          -  Presence of uncontrolled infection.&#xD;
&#xD;
          -  Unable or unwilling to discontinue use of prohibited medications listed in Section 9.2&#xD;
             for at least 14 days prior to the first dose of study drug (see Section 9.2).&#xD;
&#xD;
          -  Poorly controlled hypertension [systolic blood pressure (SBP) &gt;140 mmHg, or diastolic&#xD;
             blood pressure (DBP) &gt;90 mmHg].&#xD;
&#xD;
          -  History of cerebrovascular accident, pulmonary embolism or untreated deep venous&#xD;
             thrombosis (DVT) within the past 6 months.&#xD;
&#xD;
          -  Evidence of active bleeding or bleeding diathesis.&#xD;
&#xD;
          -  Hemoptysis within 6 weeks prior to the first dose of study drug.&#xD;
&#xD;
          -  Known endobronchial lesion(s) or involvement of large pulmonary vessel(s) by tumor.&#xD;
&#xD;
          -  History of sensitivity or allergic reaction to moxifloxacin or any member of the&#xD;
             quinolone class of antimicrobial agents.&#xD;
&#xD;
          -  Treatment with anti-cancer therapy (including chemotherapy, radiation therapy,&#xD;
             immunotherapy, biologic therapy, investigational therapy, hormonal therapy, surgery or&#xD;
             tumor embolization) within 14 days prior to the first dose of pazopanib.&#xD;
&#xD;
          -  History or presence of hepatic or renal disease or any other condition known to&#xD;
             interfere with the absorption, distribution, metabolism or excretion of drugs.&#xD;
&#xD;
          -  Prior major surgery or trauma within the past 28 days prior to the first dose of study&#xD;
             drug and/or presence of any non-healing wound, fracture or ulcer.&#xD;
&#xD;
          -  Any serious and/or unstable pre-existing medical, psychiatric, or other conditions&#xD;
             that could interfere with subject's safety, obtaining informed consent or compliance&#xD;
             to the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Heath EI, Infante J, Lewis LD, Luu T, Stephenson J, Tan AR, Kasubhai S, LoRusso P, Ma B, Suttle AB, Kleha JF, Ball HA, Dar MM. A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors. Cancer Chemother Pharmacol. 2013 Mar;71(3):565-73. doi: 10.1007/s00280-012-2030-8. Epub 2013 Jan 24.</citation>
    <PMID>23344712</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>March 12, 2009</study_first_submitted>
  <study_first_submitted_qc>March 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2009</study_first_posted>
  <last_update_submitted>November 10, 2017</last_update_submitted>
  <last_update_submitted_qc>November 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GW786034, pazopanib, moxifloxacin, ECG intervals and morphology, QTc, Holter monitor, pharmacokinetics, safety, cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

